SEARCH

SEARCH BY CITATION

References

  • 1
    Roth D. Hepatitis C virus: the nephrologist's view. Am J Kidney Dis 1995; 25: 316.
  • 2
    Pereira BJG, Wright TL, Schmid CH, Levey AS. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995; 60: 799805.
  • 3
    Mitwalli AH, Alam A, Al-Wakeel J, Al Suwaida K, Tarif N, Schaar TA, Al Adbha B, Hammad D. Effects of chronic viral hepatitis on graft survival in Saudi renal transplant patients. Nephron Clin Pract 2006; 102: c7280.
  • 4
    Morales JM, Dominguez-Gil B, Sanz-Guajardo D, Fernandez J, Escuin F. The influence of hepatitis B and hepatitis C virus infection in the recipients on late renal allograft failure. Nephrol Dial Transplant 2004; 19(Suppl. 3): iii; 7276.
  • 5
    Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 2004; 78: 745750.
  • 6
    Stehman-Breen CP, Psaty BM, Emerson S, Gretch D, Bronner M, Marsh C, Davis CL. Association of hepatitis C virus infection with mortality and graft survival in kidney-pancreas transplant recipients. Transplantation 1997; 64: 281286.
  • 7
    Takahara S, Kakimoto K, Kokado Y, Kameoka H, Ighibashi M, Kawada S, Kyo M, Nagano S, Mikami O, Okuyama A. Interferon alpha therapy for chronic active hepatitis type C after renal transplantation and allograft rejection. Int Urol Nephrol 1995; 27: 479485.
  • 8
    Luciani G, Bossola M, Muscaritoli M, Panocchia N, Ferrante A, Nanni G, Piccioni E, Tazza L, Grillo RL, Rossi Fanelli F, Castagneto M. Sustained response with negative serum HCV-mRNA and disappearance of antibodies after interferon-alpha therapy in a kidney transplant recipient with chronic active viral hepatitis C. J Nephrol 2003; 16: 417420.
  • 9
    Konishi I, Horike N, Michitawa K, Ochi N, Furukawa S, Minami H, Onji M. Renal transplant recipients with chronic hepatitis C who obtained viral response after interferon-beta therapy. Intern Med 2004; 43: 931934.
  • 10
    Ichikawa Y, Kyo M, Hanafusa T, Kohro T, Kishikawa H, Fukunishi T, Nagano S, Shinji S. A 20-year case study of a kidney transplant recipient with chronic active hepatitis C: clinical course and successful treatment for late acute rejection induced by interferon therapy. Transplantation 1998; 65: 134138.
  • 11
    Monteon FJ, Contreras AM, Espinoza L, Vazquez G, Aguilar S, Cueva L. Interferon alfa-2b in renal transplant recipients with viral hepatitis: A pilot study. Transplant Proc 1996; 28: 33063308.
  • 12
    Toth C, Pascual M, Chung RT, Graeme-Cook F, Dienstag JL, Bhan AK, Cosimi AB. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-[alpha] therapy. Transplantation 1998; 66: 12541258.
  • 13
    Harihara Y, Kurooka Y, Yanagisawa T, Kuzuhara K, Otsubo O, Kumada H. Interferon therapy in renal allograft recipients with chronic hepatitis C. Transplant Proc 1994; 26: 20752077.
  • 14
    Thervet E, Pol S, Legendre Ch, Gagnadoux MF, Cavalcanti R, Kreis H. Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. Transplantation 1994; 58: 625628.
  • 15
    Magnone M, Holley JL, Shapiro R, Scantlebury V, McCauley J, Jordan M, Vivas C, Starzl T, Johnson JP. Interferon-alpha induced acute renal allograft rejection. Transplantation 1995; 59: 10681070.
  • 16
    Rostaing L, Izopet J, Baron E, Duffault M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995; 59: 14261431.
  • 17
    Ozgur O, Boyacioglu S, Telatar H, Haberal M. Recombinant alpha-interferon in renal allograft recipients with chronic hepatitis C. Nephrol Dial Transplant 1995; 10: 21042106.
  • 18
    Yasumura T, Nakajima H, Hamashima T, Nakai I, Yoshimura N, Ohmori Y, Oka T. Long-term outcome of recombinant IFN-alpha treatment of chronic hepatitis C in kidney transplant recipients. Transplant Proc 1997; 29: 784786.
  • 19
    Durlik M, Gaciong Z, Rowinska D, Rancewicz Z, Lewandowska D, Kozlowska B, Wyzgal J, Soluch L, Walewska-Zielcka B, Rowinski W, Lao M. Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients. Transplant Int 1998; 11 (Suppl. 1): S135S139.
  • 20
    Hanafusa T, Ichikawa Y, Kishikawa H, Kyo M, Fukunishi T, Kokado Y, Okuyama A, Shinji Y, Nagano S. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998; 66: 471476.
  • 21
    Tokumoto T, Tanabe K, Ishikawa N, Simizu T, Oshima T, Noguchi S, Gouya N, Nakazawa H, Hashimoto E, Fuchinoue S, Hayashi N, Toma H. Effect of interferon-alpha treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C. Transplant Proc 1999; 31: 28872889.
  • 22
    Baid S, Tolkoff-Rubin N, Saidman S, Chung R, Williams WW, Auchinloss H, Colvin RB, Delmonico FL, Cosimi AB, Pascual M. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 2003; 3: 7478.
  • 23
    Tang S, Cheng IKP, Leung VKS, Kuok UI, Tang AWC, Ho YW, Lai KN, Chan TM. Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin. J Hepatol 2003; 39: 875878.
  • 24
    Shu KH, Lan JL, Wu MJ, Cheng CH, Chen CH, Lee WC, Chang HR, Lian JD. Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. Transplantation 2004; 77: 18841905.
  • 25
    Garnier JL, Chevallier P, Dubernard JM, Trepo C, Touraine JL, Chossegros P. Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients. Transplant Proc 1997; 29: 783.
  • 26
    Fontaine H, Vallet-Pichard A, Equi-Andrade C, Nalpas B, Verkarre V, Chaix ML, Lebray P, Sobesky R, Serpaggi J, Kreis H, Pol S. Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation 2004; 78: 853857.
  • 27
    Kamar N, Sandres-Saune K, Selves J, Ribes D, Cointault O, Durand D, Izopet J, Rostaing L. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: Effects on renal function and liver histology. Am J Kidney Dis 2003; 42: 184192.
  • 28
    Kamar N, Rostaing L, Sandres-Saune K, Ribes D, Durand D, Izopet J. Amantadine therapy in renal transplant patients with hepatitis C virus infection. J Clin Virol 2004; 30: 110114.
  • 29
    Poynard T, Conn HO. The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods. Control Clin Trials 1985; 6: 271279.
  • 30
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177188.
  • 31
    Petitti DB. Approaches to heterogeneity in meta-analysis. Statist Med 2001; 20: 36253633.
  • 32
    Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistencies in meta-analysis. Br Med J 2003; 327: 557560.
  • 33
    Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted?. Statist Med 2002; 21: 15591573.
  • 34
    Begg CB, Mazumadar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 10881098.
  • 35
    Egger M, Smith DG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629634.
  • 36
    Thevenot T, Regimbeau C, Ratziou V, Leroy V, Opolon P, Poynard T. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naïve patients. J Viral Hepat 2001; 8: 4862.
  • 37
    Cheeseman SH, Rubin RH, Stewart JA, Tolkoff-Rubin NE, Cosimi AB, Cantell K, Gilbert J, Winkle S, Herrin JT, Black PH, Russsell PS, Hirsch MS. Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation: effects on cytomegalovirus and herpes simplex virus infections. N Engl J Med 1979; 300: 13451349.
  • 38
    Lui SF, Ali A, Grundy JE, Fernando ON, Griffiths PD, Sweny P. Double-blind, placebo-controlled trial of human lymphoblastoid interferon prophylaxis of cytomegalovirus infection in renal transplant recipients. Nephrol Dial Transplant 1992; 7: 12301237.
  • 39
    Kramer P, Ten Kate FWJ, Bijnen AB, Jeekel J, Weimar W. Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1984; 1: 989990.
  • 40
    Kovarik J, Mayer G, Pohanka E, Schwartz M, Traindl O, Graf H, Smolen J. Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Cytomegalovirus infection prophylaxis leading to an increase incidence of irreversible rejection. Transplantation 1988; 45: 402405.
  • 41
    Halloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS. The significance of anti-class I antibody response. Clinical and pathologic features of anti-class I mediated rejection. Transplantation 1990; 49: 8591.
  • 42
    Heydtmann M, Freshwater D, Dudley T, Lai V, Palmer S, Hubscher S, Mutimer D. Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation. Am J Transplant 2006; 6: 825833.
  • 43
    Rhodes J, Jones DH, Bleehen NM. Increased expression of human monocyte HLA-DR antigens and Fc-gamma receptors in response to human interferon in vivo. Clin Exp Immunol 1983; 53: 739743.
  • 44
    Samuel D. Hepatitis C, interferon, and risk of rejection after liver transplantation. Liver Transplant 2004; 10: 868871.
  • 45
    Fleiss JL, Gross AJ. Meta-analysis in epidemiology, with special reference to studies of association between exposure to environmental tobacco smoke and lung cancer: a critique. J Clin Epidemiol 1991; 44: 127139.
  • 46
    Kamar N, Toupance O, Buchler M, Sandes-Saune K, Izopet J, Durand D, Rostaing L. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003; 14: 20922098.
  • 47
    Bunnapradist S, Fabrizi F, Vierling J, Martin P, Moudgil A, Kamil E, Jordan S. Hepatitis C therapy with long term remission after renal transplantation. Int J Artif Organs 2002; 25: 11891193.
  • 48
    Grgurevic I, Vince A, Buljevac M, Banic M, Jeren-Strujic B, Kes P, Kujundzic M, Leko N, Lukic IK, Slavicek J. Efficacy of interferon-alpha in the treatment of chronic hepatitis C in dialysis patients: two therapeutic protocols compared. Nephron Clin Pract 2005; 103: c8c11.
  • 49
    Mahmoud IM, Sobh M, El-Habashi AF, Sally ST, El-Baz M, El-Sawy E, Ghoneim MA. Interferon therapy in hemodialysis patients with chronic hepatitis C: Study of tolerance, efficacy and post-transplantation course. Nephron Clin Pract 2005; 100: c133c139.
  • 50
    Rocha CM, Perez RM, Ferreira AP, Carvalho-Filho RJ, Pace FH, Silva IS, Pestana JOM, Lanzoni VP, Silva AE, Ferraz MLG. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver International 2006; 26: 305310.
  • 51
    Russo MW, Ghalib R, Sigal S, Joshi V. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2006; 21: 437443.
  • 52
    Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepatitis 2006; 13: 316321.